Archive · 6 Aug 2026
Why Kacholia, Singhania ignored falling promoter stakes in healthcare
Imagine a company is like a big pizza.
The people who started the company, called promoters, own big slices.
If the news says promoters own fewer slices, people often worry that the promoters are leaving.
But sometimes the company makes the pizza bigger by baking new slices and selling them to others.
Then everyone's slice looks smaller, even though nobody sold anything.
This article looks at two medicine companies in India.
One makes medicines that fight cancer, while the other is trying to invent new medicines for brain diseases like Alzheimer's.
Famous investors who own slices in these companies did not rush to sell.
The article says we should read the fine print of company filings before worrying about percentages.
Ashish Kacholia holds close to an 11% stake in Beta Drugs Ltd, and Sunil Singhania's Abakkus Diversified Alpha Fund holds 1.00% of Suven Life Sciences Ltd.
Beta Drugs' promoter holding fell from 66.73% (June 2025) to 59.10% (June 2026), partly attributed to a Rs 117 cr preferential issue while DII holding rose from 0.29% to 6.23%.
Suven Life Sciences' promoter stake dropped from 70.08% to 65.47% in July 2026, explained by the board-approved conversion of 1.85 cr warrants into equity for Rs 248.84 cr.
Beta Drugs posted its strongest quarter on record in June 2026 with sales up 25% year on year to Rs 126 cr and net profit up 35% to Rs 16 cr.
Suven Life Sciences reported an FY26 net loss of Rs 276 cr on sales of just Rs 7 cr, yet its stock is up 73% over three years and trades at about 14 times book value.
- Who
- Ashish Kacholia holds nearly an 11% stake in Beta Drugs Ltd, while Sunil Singhania's Abakkus Diversified Alpha Fund holds 1.00% of Suven Life Sciences Ltd.
- What
- An analysis of why falling promoter stakes at two healthcare companies, Beta Drugs Ltd and Suven Life Sciences Ltd, do not necessarily mean promoters are selling shares.
- When
- Shareholding filings between September 2025 and July 2026, with share prices as of 5 August 2026.
- Where
- India-listed companies; Suven Life Sciences also plans a wholly owned subsidiary in Singapore and will present at AAIC 2026 in London.
- Why
- Promoter percentages fall when companies issue new shares through preferential issues or warrant conversions, diluting all existing holders even without any stake sales.
The Skeptic's View
The Corporate-Actions View
What Falling Promoter Stakes Mean
The Skeptic's View
Retail investors treat the drops in promoter holdings at Beta Drugs and Suven Life Sciences as red flags that the people running the companies are selling out.
The Corporate-Actions View
The article argues the declines mainly stem from fresh shares created via a preferential issue and warrant conversions, which shrink every holder's percentage without any promoter sales.
Investing in Loss-Making Suven Life Sciences
The Skeptic's View
With six straight loss-making years, FY26 sales of just Rs 7 cr, a net loss of Rs 276 cr and ROCE of -80%, the stock is extremely expensive and risky with no earnings to fall back on.
The Corporate-Actions View
Investors are pricing the pipeline: Phase 3 molecule Masupirdine and Phase 2 Usmarapride, funded by Rs 250 cr of warrant money, with the stock still logging a 73% three-year price CAGR.
- Beta Drugs market cap
- Rs 2,602 cr
- Beta Drugs promoter stake
- 66.73% (June 2025) to 59.10% (June 2026)
- Beta Drugs share price (5 Aug 2026)
- Rs 2,347, up 590% in 5 years
- Suven Life Sciences market cap
- Rs 8,764 cr
- Suven promoter stake
- 70.08% (June 2026) to 65.47% (July 2026)
- Suven FY26 performance
- Sales Rs 7 cr; net loss Rs 276 cr
- Abakkus fund stake in Suven
- 1.00%, worth about Rs 87 cr
- Warrant conversion
- 1.85 cr warrants converted into equity for Rs 248.84 cr (approved 8 July 2026)